CJC-1295 dosage: the doses used in published research

Doses used in CJC-1295 research

<a id="doses-used"></a>

Doses Used in CJC-1295 Research

CJC-1295 dosage in the published record is reported as micrograms per kilogram in pharmacokinetic studies, not as fixed human protocols. Human PK studies used single subcutaneous doses of 30, 60 or 90 ug/kg ^[1][3]. The GHRH-knockout mouse growth study used 2 ug per dose at 24-72 hour intervals ^[4]. These are the doses administered in studies; they are not a human-use recommendation, and CJC-1295 is not approved for human use anywhere.

The community 'protocols' that circulate for no-DAC Modified GRF 1-29 and for CJC-1295/ipamorelin commonly cite 100-300 ug fixed doses, but these are not derived from controlled human trials ^[1]. The gap between the published microgram-per-kilogram PK doses and the round fixed numbers traded in forums is itself part of the record worth naming.

The published dose-response is also informative about shape. The human PK study found the GH and IGF-1 response was dose-dependent across the 30 and 60 ug/kg doses — higher doses produced larger and more sustained increases, with mean GH rising 2- to 10-fold and IGF-1 1.5- to 3-fold depending on dose ^[1]. In the GHRH-knockout mouse, the variable that mattered most was not the per-dose amount but the interval: 2 ug once every 24 hours normalized growth, while the same dose at 48- or 72-hour intervals was progressively less effective ^[4]. The record characterizes how the molecule responds to dose and frequency in study conditions; it does not translate those observations into a human regimen, and CJC-1295 remains unapproved for human use.

CJC-1295 DAC doses in studies

<a id="dac-doses"></a>

CJC-1295 DAC Doses in Studies

The published DAC human pharmacokinetic work used 30 or 60 ug/kg subcutaneously, and because of the multi-day half-life a single dose elevated IGF-1 for 9-11 days ^[1]. This is the distinguishing feature of the DAC dose-response: the duration is set by the albumin anchor, not by the dose interval, which is why the GHRH-knockout study found once-daily dosing sufficient to normalize growth ^[4].

The Ionescu/Frohman study used 60 or 90 ug/kg single doses and measured the GH and IGF-1 response one week out ^[3]. All of this is research context describing what studies administered — not dosing guidance for any use.

Routes studied

<a id="routes"></a>

Routes Studied

Published studies used subcutaneous injection as the primary route, with intravenous administration in the early GRF(1-29) pharmacokinetic work ^[1]. This describes the research route, not a human-use instruction. Oral bioavailability is negligible because CJC-1295 is a peptide, so the subcutaneous route is the one with a characterized profile ^[2].

Reconstitution and Handling in Research Settings

<a id="reconstitution"></a>

In research handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; the four substitutions confer DPP-IV/protease resistance, and DAC conjugation confers the multi-day duration ^[1][2]. Oral bioavailability is negligible, so studies use subcutaneous injection. This describes laboratory handling practice in the literature, not a preparation instruction for human use.

CJC-1295 and ipamorelin in combination research

<a id="combination"></a>

CJC-1295 and Ipamorelin in Combination Research

There are no controlled human trials of fixed CJC-1295/ipamorelin protocols; the circulating community doses are not derived from published research ^[13]. The scientific basis for pairing them is the two-receptor synergy — a GHRH analog and a GHRP acting on distinct receptors to produce GH release greater than either alone ^[13][14]. The mechanism is real; the specific combination protocol is not from controlled trials.

What the record supports is the rationale, not a regimen. Ipamorelin's GH-releasing pharmacokinetics have been modeled in swine ^[14], and the GHRH-plus-GHRP synergy is established mechanistically ^[13] — but the dose and ratio combinations sold for the pairing have no controlled human efficacy data behind them.